Article Text

Download PDFPDF
Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity
  1. Marko Brinar,
  2. Isabelle Cleynen,
  3. Tamara Coopmans,
  4. Gert Van Assche,
  5. Paul Rutgeerts,
  6. Severine Vermeire
  1. Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
  1. Correspondence to Dr Severine Vermeire, Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium; severine.vermeire{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the work by Foell et al in which the authors report increased serum levels of the protein S100A12, a marker of neutrophil activation, in patients with Crohn's disease and ulcerative colitis in comparison with healthy controls.1 They also demonstrated a correlation between S100A12 in the serum and disease activity as well as a prompt decrease of S100A12 levels in response to infliximab therapy. More recently, the same group showed that faecal S100A12 had even superior sensitivity and specificity than faecal calprotectin in distinguishing active inflammatory bowel disease (IBD) from healthy controls.2 All together, these findings make S100A12 a promising biomarker in IBD.

As both studies included only few patients, we wanted to further investigate the accuracy of serum S100A12 in a larger cohort of patients and controls. In brief, S100A12 was determined in …

View Full Text


  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Ethical Committee, University Hospital Gathuisberg.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Linked Articles

  • PostScript
    Dirk Foell